Trastuzumab emtansine associated nodular regenerative hyperplasia: A case report and review of literature L.H. Prochaska, I. Damjanov, R.M. Ash, J.C. Olson, Q.J. Khan, P. Sharma Cancer Treatment and Research Communications Volume 5, Pages 26-30 (January 2016) DOI: 10.1016/j.ctrc.2015.11.008 Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 1 CT imaging changes following T-DM1 initiation. Cancer Treatment and Research Communications 2016 5, 26-30DOI: (10.1016/j.ctrc.2015.11.008) Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 2 Liver function tests (A) and platelet levels (B) in relation to T-DM1 initiation and discontinuation. Cancer Treatment and Research Communications 2016 5, 26-30DOI: (10.1016/j.ctrc.2015.11.008) Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 3 Nodular regenerative hyperplasia (A) Hepatocytes form indistinct small nodules (arrows) compressing the surrounding cells. H&E×160. (B) Reticulin stain outlines the nodules and the compressed hepatocytes around them (×160). (C) Immunohistochemical stain with antibodies to cytokeratin that stains selectively the bile ducts and ductules. The lower lobule shows a ductal reaction around a portal tract missing the primary duct (bottom part of the figure). In the upper lobule there is a “blush-like” staining of periportal hepatocytes undergoing ductal metaplasia (×220). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Cancer Treatment and Research Communications 2016 5, 26-30DOI: (10.1016/j.ctrc.2015.11.008) Copyright © 2015 Elsevier Ltd Terms and Conditions
Fig. 4 Treatment history timeline leading to development of NRH. Cancer Treatment and Research Communications 2016 5, 26-30DOI: (10.1016/j.ctrc.2015.11.008) Copyright © 2015 Elsevier Ltd Terms and Conditions